Endeavor BioMedicines reports mid-stage trial success for IPF drug, suggests disease reversal potential

Endeavor BioMedicines announced that its experimental therapy for idiopathic pulmonary fibrosis has met its primary goals in a Phase 2 study. The company said the mid‑stage trial showed signs that the drug could reverse the progression of the chronic lung disease.

The trial evaluated patients with IPF, a condition with limited treatment options and a poor prognosis. While detailed efficacy data were not disclosed, the company highlighted the potential for disease modification rather than just symptom management.

If the findings are confirmed in later studies, the therapy could represent a significant advance for patients and investors focused on respiratory biotech. Endeavor plans to advance the program toward a pivotal trial later this year.